We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)
Introduction : Safety of Avastin in Lung ( MO19390 ) was an international , open-label , single-arm study , which assessed the safety and efficacy of first-line bevacizumab ( Avastin ® ) in combination with st and ard chemotherapy in patients ( n = 2212 ) with advanced or recurrent non-small cell lung cancer ( NSCLC ) . A preplanned subgroup analysis was performed to examine these outcomes in elderly patients older than 65 years . Methods : Eligible patients with nonsquamous NSCLC received up to six cycles of bevacizumab ( 7.5 or 15 mg/kg ) plus any st and ard of care chemotherapy . Patients who did not experience disease progression after induction therapy continued bevacizumab therapy until disease progression or unacceptable toxicity . The primary end point was safety ; secondary end points included time to disease progression ( TTP ) and overall survival ( OS ) . Results : Data were evaluated for 623 patients older than 65 years ( mean age 70.6 ) . The majority were Whites ( 86.2 % ) with stage IV disease ( 79.7 % ) and had adenocarcinoma ( 83.5 % ) . The incidence of adverse events ( AEs ) of special interest was similar for elderly and younger patients ( any grade bleeding 38.2 % versus 38.3 % ; any grade hypertension 33.1 % versus 30.6 % ; any grade proteinuria 33.4 % versus 29.3 % ) . Most AEs were grade less than or equal to 2 . Serious AEs were reported in 45.3 and 34.7 % of elderly and younger patients , respectively . Median OS was similar in elderly and younger patients ( 14.6 months in both age groups ) , as were TTP ( 8.2 versus 7.6 months ) , response rate ( 49.3 % versus 52.4 % ) , and disease control rate ( 89.3 % versus 88.4 % ) . Similar results were seen in a post hoc comparison of the older than 70 years and 70 years or younger subgroups : TTP was 8.6 months versus 7.7 months , respectively ; OS was 14.6 months in both subgroups ; response rate was 49 % and 52 % , respectively ; incidence of AEs of special interest was comparable . Conclusion : Patients older than 65 years with nonsquamous NSCLC derive a similar clinical benefit from first-line bevacizumab-based therapy as their younger counterparts and do not experience increased toxicity
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV